Exelixis focuses on future growth despite COSMIC-313 trial challenges
The final result of the COSMIC-313 trial is not the only disappointment for Exelixis.
Comment & Opinion
SCOPE 2025: investors share optimism and obstacles for AI in clinical operations
Pfizer’s bet on gene therapies in haemophilia has been a bust
Vietnam eases foreign investment restrictions in amended pharmaceutical law
NICE approval of Casgevy: a new era for sickle cell disease treatments in the UK
FDA approvals decline but drug innovation remains strong even among small sponsors
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market
GLP-1 receptor agonists could hold promise for opioid use disorder treatment
